10x Genomics, Inc. (TXG)

NasdaqGS · Health Information Services

61.65
+1.67 (+2.78%)
Updated Sep 2, 10:05 PM ET
AI Rating
Buy
Overall Score
68
Trend
100
Momentum
64
Risk
24

Scores are generated from technical indicators for educational purposes and are not a recommendation to buy or sell.

Price history

Daily closes and volume
Aug 18, 2025 260 sessions Aug 28, 2026

AI Analysis

10x Genomics, Inc. is trading at $61.65, up 2.78% on the session. The 50 day average sits at $48.07 and the 200 day at $27.80, which puts the stock in a uptrend. RSI is at 61.8, which reads as strong, and MACD is bearish crossover. Volume is below average.

The nearest support is around $55.25 with resistance near $66.94, so that band frames the current range. Average daily movement is roughly $3.66, or about 5.9% of the share price, which is what any stop placement has to allow for. The overall health score of 68 out of 100 combines a trend score of 100, momentum of 64 and a risk score of 24.

Technical indicators

RSI (14)
61.8
strong
MACD
4.943
bearish crossover
SMA 20
57.65
SMA 50
48.07
SMA 200
27.80
uptrend
ATR (14)
3.66
avg daily range
Support
55.25
Resistance
66.94
Volume vs 20d
0.71x
below average
Volatility
82.5%
annualised
1 month
+24.50%
3 months
+117.42%

About 10x Genomics, Inc.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Company website

Stay Ahead of the Market

Get daily AI insights, market updates, and trade opportunities delivered to your inbox.